• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.44% Nasdaq Down0.37%

    OncoMed Pharmaceuticals, Inc. (OMED)

    22.85 Down 0.78(3.30%) Nov 30, 4:00PM EST
    |After Hours : 22.85 Down 0.00 (0.01%) Nov 30, 5:36PM EST
    ProfileGet Profile for:
    OncoMed Pharmaceuticals, Inc.
    800 Chesapeake Drive
    Redwood City, CA 94063
    United States - Map
    Phone: 650-995-8200
    Fax: 650-995-8600
    Website: http://www.oncomed.com

    Index Membership:N/A
    Full Time Employees:108

    Business Summary 

    OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has completed preclinical trial that targets and inhibits DLL4 and vascular endothelial growth factor (VEGF); Tarextumab (Anti-Notch2/3, OMP-59R5), a human monoclonal antibody that targets the Notch2 and Notch3 receptors that is in Phase II clinical trials; Brontictuzumab (Anti-Notch1, OMP-52M51), a human monoclonal antibody, which completed single-agent Phase I trial for the treatment of solid tumor; and Vantictumab ((Anti-Fzd7, OMP-18R5) that completed a Phase I single-agent trial in tumor patients. Its products also include Ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based Frizzled8 receptor or Fzd8, which is in Phase I single agent trial; Wnt biologic #3, an additional bispecific biologic product candidate in preclinical studies; Wnt small molecule inhibitors, which is in preclinical testing; and RSPO-LGR, a CSC pathway that is in preclinical study of antibodies. OncoMed Pharmaceuticals, Inc. has strategic alliances with GlaxoSmithKline LLC to develop anti-CSC antibody therapeutics targeting the Notch signaling pathway; Bayer Pharma AG for anti-CSC biologic and small molecule therapeutics targeting the Wnt signaling pathway; and Celgene Corporation for anti-CSC product candidates. The company was founded in 2004 and is headquartered in Redwood City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on OncoMed Pharmaceuticals, Inc.

    Corporate Governance 
    OncoMed Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2015 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Paul J. Hastings , 55
    Chairman, Chief Exec. Officer and Pres
    Dr. John A. Lewicki Ph.D., 63
    Chief Scientific Officer and Exec. VP
    Dr. Jakob Dupont M.D., 50
    Chief Medical Officer and Sr. VP
    Mr. Sunil Patel , 43
    Chief Financial Officer and Sr. VP of Corp. Devel. & Fin.
    Dr. Alicia J. Hager J.D., Ph.D., 45
    VP and Gen. Counsel
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders